A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were associated with reduced rates of 3-point major adverse cardiovascular events (3P-MACE) and hospitalization for heart failure (HHF) compared to dipeptidyl peptidase 4 inhibitors (DPP-4is). Compared to GLP1-RAs, SGLT-2is were associated with reduced rates of HHF. The study included 35,679 participants aged ≥70 years who were new users (DPP-4is: 62%, GLP1-RAs: 16%, SGLT-2is: 23%) between 2012 and 2020. In the as-treated analysis, GLP1-RAs and SGLT-2is were associated with significantly reduced rates of 3P-MACE and HHF compared to DPP-4is. The overall incidence rate ratios (IRR) for 3P-MACE was 0.68 (GLP1-RAs vs. DPP4is) and 0.65 (SGLT-2is vs. DPP4is), while for HHF the IRR was 0.81 (GLP1-RAs vs. DPP4is) and 0.60 (SGLT-2is vs. DPP4is). These effects were predominantly independent of age. Compared to GLP1-RAs, SGLT-2is were associated with a significant reduction of HHF, with an overall IRR of 0.75. No significant difference was observed between SGLT-2is and GLP1-RAs on 3P-MACE. The results confirm the cardiovascular benefits of newer glucose-lowering drugs in elderly populations and support current guidelines. Source: https://www.thelancet.com/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.